Related to this topic: Patient+ | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Choroidal Melanoma

Choroidal melanoma is the most common primary malignant intraocular tumour. It is also the second most common type of primary malignant melanoma in the body. However, it is relatively uncommon.

Pathogenesis

Primary choroidal melanoma arises from melanocytes within the choroid. It is thought that they develop from pre-existing melanocytic naevi.Their colours vary from darkly pigmented to purely amelanotic. They are usually domed-shaped. If they break through the Bruch membrane as they grow, they look like a mushroom. They can also be bilobular, multilobular, and diffuse in shape.
Choroidal melanomas usually cause death secondary to distant metastases rather than local spread. Its metastatic potential depends on the histopathologic aggressiveness of the tumor cells. Commonly the tumour may metastasise before diagnosis. Metastases are usually to the liver, but may also involve the lung, bone, skin, and CNS. Less frequently, choroidal melanoma can metastasise locally into the orbit, the conjunctiva or the maxillo-facial bones.1

Epidemiology
  • White people of northern European descent are most often affected. Scandinavian countries have an incidence of about 7.5 cases per million population, per year.2
  • It is rarely found among black people. Hispanics and Asians are thought to have a small risk compared to whites.
  • There is a slightly higher incidence in men for all age groups, except from 20-39 years, when a small predilection exists for women.
  • Incidence peaks at around 55 years of age.

Risk factors

Light-colored irises. There is some evidence that sunlight exposure contributes to development of choroidal melanoma.

Presentation

They may be asymptomatic but found incidentally during ophthalmoscopy. In general, those of posterior origin are more likely to be diagnosed. Diagnosis is based on clinical findings and scan results.

Symptoms

These may include:

  • Blurred visual acuity
  • A paracentral scotoma
  • Painless and progressive visual field loss
  • Floaters
  • Occasionally severe ocular pain

NB:
History of weight loss, fatigue, cough, or change in bowel or bladder habits is suggestive of primary non-ocular malignancy, with choroidal metastasis.

Signs

  • Painless visual loss
  • Occasionally inflammation and pain
  • Dome-shaped
  • Varying colours
Investigations
  • LFT's; assess the likelihood of metastasis.
  • CXR; exclude lung metastases.
  • A-scan ultrasound of the eye; performing sequential scans is important in cases of diagnostic uncertainty.
  • B-scan ultrasound of the eye is used to evaluate any posterior segment mass. B-scan is used to:
    • Help establish the diagnosis
    • Evaluate possible extraocular extension
    • Estimate tumour size for periodic observation
    • Plan treatment

CT scan of the eye is more expensive than ultrasound, and less sensitive.

Management

There are several ways to manage choroidal melanomas. Factors to take into account include:

  • Visual acuity of the affected eye
  • Visual acuity of the contralateral eye
  • Size of the tumour
  • Age and general health of the patient
  • Ocular structures involved
  • Presence of metastases

Choice of treatment of choroidal melanoma remains controversial. Although enucleation has been the treatment of choice in the past, research has shown that vision-sparing approaches might offer similar degrees of tumour control. A multicentre randomised trial by the Collaborative Ocular Melanoma Study (COMS) Group showed that patient survival after treatment with plaque radiotherapy is similar to enucleation for medium-size melanoma.3

Non-Surgical

  • Observation may be acceptable for posterior uveal tumours where diagnosis is not well established. In particular, tumours of less than 2-2.5 mm in elevation and 10 mm in diameter can be observed until growth is documented.4
  • Plaque brachytherapy is a widely accepted alternative to enucleation for medium size posterior uveal melanomas (<10 mm in height and <15 mm in diameter). It is associated with cataract development in up to 83% patients.5
  • External beam irradiation using charged particles, either protons or helium ions, is a frequently used alternative method to treat medium size choroidal melanomas (<10 mm in height and <15 mm in diameter), although it has been used for larger tumours. It has similar indications and success rates to plaque brachytherapy.6
  • Laser photocoagulation and transpupillary thermotherapy are used in selected small choroidal melanomas, when they are located away from the fovea and are less than 3 mm in thickness.

Surgical

  • Enucleation is the classic approach to choroidal melanomas and has been the preferred treatment for large (basal diameter>15 mm and height >10 mm) and complicated tumours, which compromise visual function, and where other therapies tend to fail.
  • Block excision, or sclerouvectomy, is an alternative treatment method for choroidal melanomas. It is reserved for small tumours covering less than a one third of the globe's circumference.
  • Orbital exenteration is a radical treatment reserved for cases with widespread orbital extension. Patients with such advanced melanomas are likely to have extensive distant metastases and poor prognosis for survival, with or without orbital exenteration surgery.
Prognosis

Approx. 30-50% of patients die within 10 years from diagnosis and treatment.2 It is usually secondary to distant metastases, and the risk is greatest in larger tumors.


Document References
  1. Pandey M, Prakash O, Mathews A, et al; Choroidal melanoma metastasizing to maxillofacial bones. World J Surg Oncol. 2007 Mar 8;5:30. [abstract]
  2. Garcia-Vlaenzuela E; Melanoma, choroidal.; emedicine September 2006
  3. No authors listed; The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006 Dec;124(12):1684-93. [abstract]
  4. Murray TG, Sobrin L; The case for observational management of suspected small choroidal melanoma. Arch Ophthalmol. 2006 Sep;124(9):1342-4.
  5. No authors listed; Incidence of Cataract and Outcomes after Cataract Surgery in the First 5 Years after Iodine 125 Brachytherapy in the Collaborative Ocular Melanoma Study COMS Report No. 27. Ophthalmology. 2007 Mar 3;. [abstract]
  6. Robertson DM; Changing concepts in the management of choroidal melanoma. Am J Ophthalmol. 2003 Jul;136(1):161-70. [abstract]
Acknowledgements EMIS is grateful to Dr Hayley Willacy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 4059
Document Version: 20
DocRef: bgp25991
Last Updated: 20 Apr 2007
Review Date: 19 Apr 2009
Patient UK Current Health News










Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site



PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page